Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats by Ireson, C R et al.
Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor
667 COUMATE and its sequestration into red blood cells in rats
CR Ireson
1, SK Chander
1, A Purohit
1, DC Parish
1, LWL Woo
2, BVL Potter
2 and MJ Reed*,1
1Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary’s Hospital, London W2 1NY, UK;
2Medicinal
Chemistry and Sterix Ltd, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK
Breast cancer is a major cause of mortality in Western countries and there is an urgent requirement for novel treatment strategies.
The nonsteroidal sulphatase inhibitor 667 COUMATE inhibits hepatic steroid sulphatase and growth of oestrone sulphate stimulated
tumours in the nitrosomethylurea-induced rat mammary model. Other compounds that contain an aryl sulphamate moiety, for
example, oestrone-3-O-sulphamate, are sequestered into red blood cells (RBCs). The aims of this study were to determine the
pharmacokinetics of 667 COUMATE and to investigate its sequestration into RBCs. We administered a single p.o. or i.v. dose
(10mgkg
 1) of 667 COUMATE to rats and used a high-performance liquid chromatography method to measure the levels of the
agent and its putative metabolites in plasma. 667 COUMATE had a bioavailability of 95% and could be detected in plasma for up to
8h. Using two independent analytical methods, we demonstrated that 667 COUMATE is sequestered by RBCs both ex vivo and in
vivo. Previous investigations have revealed that 667 COUMATE is rapidly degraded in plasma ex vivo. In this study, we demonstrate
that 667 COUMATE is stabilised due to its sequestration into RBCs. In conclusion, the pharmacological efficacy and high oral
bioavailability of 667 COUMATE may be partly a consequence of the ability of RBCs to both protect the agent from metabolic
degradation and facilitate its transport to tissues. These data support the further clinical evaluation of this novel endocrine therapeutic
agent.
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Breast cancer is the most common form of cancer among women
in the developed world (Parkin et al, 1999). Oestrogens are
considered to be the most important hormones that influence the
development and growth of breast tumours (James and Reed, 1980;
Bernstein and Ross, 1993). In postmenopausal women, in whom
breast cancer most frequently occurs, oestrogens are formed
exclusively in peripheral tissues. There are two main pathways by
which oestrogens can be synthesised in peripheral tissues, that is,
the aromatase and sulphatase routes. In the aromatase pathway,
androstenedione, secreted mainly by the adrenal cortex, is
converted to oestrone by the aromatase enzyme complex. Much
of this oestrone formed via the aromatase route can be converted
to oestrone sulphate (E1S) by sulphotransferase enzymes (Strott,
2002). Plasma and tissue concentrations of E1S in humans are
considerably higher than those of unconjugated oestrone and
oestradiol (Noel et al, 1981; Pasqualini et al, 1996). It has been
suggested that the high plasma and tissue levels of E1S may act as a
reservoir for the formation of biologically active steroids by the
action of steroid sulphatase (STS) (Reed et al, 1996). The activity of
STS, the enzyme that hydrolyses E1S to oestrone, is considerably
higher than that of the aromatase enzyme in breast tumours (James
et al, 1987). The potential importance of the sulphatase pathway
for the in situ formation of oestrogen from oestrogen sulphates was
recently demonstrated in a study in which MCF-7 breast cancer
cells transfected with either vector (MCF-7v) or vector containing
the STS cDNA (MCF-7STS) were inoculated into the flanks of
ovariectomised nude mice (James et al, 2001). The incidence of
tumours in mice bearing MCF-7STS cells and supplemented with
oestradiol sulphate (71%) was significantly higher than in animals
bearing this cell line but not supplemented with oestradiol sulphate
(21%). Supplementation with oestradiol sulphate, and subsequent
hepatic hydrolysis, was not sufficient to stimulate the growth of
MCF-7 cells, thus demonstrating the importance of in situ
oestrogen synthesis in supporting tumour growth. Recently, four
studies have confirmed that a high level of STS mRNA expression
in tumours was associated with a poor prognosis in women with
breast cancer (Utsumi et al, 1999; Miyoshi et al, 2003; Suzuki et al,
2003; Yoshimura et al, 2004). In contrast, aromatase mRNA
expression had no prognostic value. Since many tumours will fail
to respond to endocrine therapy, or progress after a relatively short
period of time, it is necessary to continue to develop new drugs for
the treatment of breast cancer. A number of potent STS inhibitors
have now been developed (Howarth et al, 1994; Reed et al, 1996), of
which 667 COUMATE (Figure 1) (Purohit et al, 2000; Woo et al,
2000) has recently entered a Phase I clinical trial in postmeno-
pausal women with breast cancer.
While there is evidence for the efficacy of 667 COUMATE in vivo
in the rat, its pharmacokinetics have not been investigated. In
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sorder to establish the pharmacokinetic parameters of 667
COUMATE, we administered a single oral (p.o.) or intravenous
(i.v.) dose of the agent to female rats. In a previous study, we
investigated the stability of 667 COUMATE in plasma (Ireson et al,
2003). When the drug was incubated with plasma, 80% of the agent
was removed by 4h. The major degradation product was 667
COUMARIN (Figure 1), which was devoid of any STS inhibitory
activity. Paradoxically, a single dose of 667 COUMATE has been
shown to inhibit STS in vivo in the rat for up to 24h (Purohit et al,
2001). 667 COUMATE contains a sulphamate moiety (Figure 1). It
is apparent that other agents containing this chemical group, for
example, oestrone-3-O-sulphamate (EMATE), are sequestered into
red blood cells (RBCs) after absorption in which they are able to
transit the liver without first pass metabolism and inactivation
(Elger et al, 1995, 1998). It is known that a number of
sulphonamide drugs, which are structurally related to sulpha-
mates, are also transported in RBCs (Lin et al, 1992). Their
transport in these cells is facilitated by binding reversibly to
carbonic anhydrase II (CAII), which is expressed in the cytoplasm
of RBCs, via coordination of the sulphamate anion to the active site
zinc atom.
We hypothesised that 667 COUMATE is also sequestered into
RBCs and that this may explain, at least in part, the efficacy of the
agent in vivo in the rat despite its modest stability ex vivo in
plasma. Indeed, 667 COUMATE was shown to inhibit human CAII
with an IC50 value of 17nM, clearly demonstrating that this
inhibitor has a high affinity for the enzyme (Ho et al, 2003; Vicker
et al, 2003). We investigated this hypothesis using three
experimental settings: uptake of radiolabelled 667 COUMATE ex
vivo into rat RBCs, uptake of unlabelled 667 COUMATE ex vivo
into RBCs and uptake of unlabelled 667 COUMATE in vivo in the
rat following a single p.o. or i.v. dose. In order to ascertain whether
667 COUMATE is stabilised by the presence of RBCs, we compared
the ratio of 667 COUMATE/667 COUMARIN following incubation
of the agent with rat plasma or whole blood.
The aims of this study were to determine the pharmacokinetic
parameters of 667 COUMATE in the rat and to investigate the
hypothesis that this agent is sequestered and stabilised by RBCs.
These data will be useful for the design of clinical studies of this
STS inhibitor.
MATERIALS AND METHODS
Chemicals and reagents
The following reagents were purchased from the suppliers listed:
high-performance liquid chromatography (HPLC) grade acetoni-
trile, diethyl ether (Fisher Scientific UK Limited, Loughborough,
Leicestershire, UK); halothane (Astra Zeneca, Cheshire, UK);
tetrahydrofuran (THF), acetazolamide, polyethylene glycol-400
(PEG-400), citric acid and citric acid trisodium salt (Sigma-Aldrich
Comp. Ltd, Poole, Dorset, UK); water (ICN Biomedicals, Aurora,
OH, USA); 0.45mM HPLC filters (Paul Gelman Laboratories,
Portsmouth, UK). 667 COUMATE was prepared as described
previously (Woo et al, 2000). Radiolabelled 667 COUMATE
(30Cimmol
 1) was custom synthesized by Sibtech Inc., CT, USA.
Pharmacokinetic study
Female Wistar (155–165g) rats were purchased from Charles
River UK Ltd (Margate, Kent, UK) and housed in a dedicated
animal facility. Rats received RM1 rodent maintenance diet (SDS,
Kent, UK), water ad libitum and were maintained in positive
pressure isolators under a 12h light–dark cycle. These experi-
ments were approved by the Imperial College Ethical Review
Committee and met the standards required by the UKCCCR
guidelines (Workman et al, 1998). Rats received 667 COUMATE
(10mgkg
 1, p.o. or i.v.) with control animals receiving vehicle
only (THF:PEG-400:water, 1:6:3 (in volume)). Three rats were
used for each time point. Rats were subjected to terminal
anaesthesia (halothane) and blood was removed by cardiac
puncture at 2.5, 5, 15, 30 and 45min and 1, 3, 8, 16 and 24h
after i.v. administration. Following p.o. administration of 667
COUMATE, blood samples were taken at 5, 15, 30 and 45min and
1, 2, 3, 6, 8, 16, 24 and 48h. In order to stabilise 667 COUMATE,
whole blood was acidified by mixing with one part of 1 M citrate
buffer (pH 3) to nine parts of blood. Plasma and RBCs were
prepared from whole blood by centrifugation (2800g,4 1C, 15min).
667 COUMATE and 667 COUMARIN were extracted from plasma
(0.5ml) with diethyl ether (4ml) and the aqueous phase was frozen
in a methanol:solid carbon dioxide mixture. 7-Hydroxycoumarin
(3mgml
 1) was used as an internal standard. The organic phase
was decanted to a fresh tube and evaporated to dryness under a
stream of air at room temperature. The extraction of 667
COUMATE from RBCs used a method that was similar, but not
identical, to one developed for the extraction of topotecan from
whole blood (Loos et al, 2002). Briefly, RBCs were mixed with
blank plasma (1:1, vv
 1) and mixed by inversion in order to
reconstitute ‘whole blood’. 7-Hydroxycoumarin (3mgml
 1) was
added to the whole blood (500ml). The extraction of the internal
standard, 667 COUMATE and 667 COUMARIN into three times
the volume of diethyl either was facilitated by vortexing (5min)
and incubating the mixture on ice (10min). Samples were thawed,
vortexed for a further 5min, centrifuged (15000g, 15min) and the
supernatant was removed and filtered (0.45mM, acrodisc CR
PTFE). The diethyl ether was removed under a stream of air.
The extraction efficiencies for 667 COUMATE from plasma and
whole blood were 7675 and 4176% (n¼6), respectively.
The residues were stored at  201C in preparation for HPLC
analysis.
Figure 1 Chemical structures of 3-Hydroxy-6-oxo-8,9,10,11-tetrahydro-
7H-cyclohepta-[c] [1] benzopyran (667 COUMARIN) and 6-oxo-
8,9,10,11-tetrahydro-7H-cyclohepta-[c] [1] benzopyran-3-O-sulphamate
(667 COUMATE).
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Pharmacokinetic parameters were calculated using WinNonlin
software (Pharsight Corporation, Mountview, CA, USA). The area
under the curve (AUC) was calculated using the linear trapezoidal
method with extrapolation of the terminal phase to infinity. Other
parameters calculated were as follows: elimination rate constant
(b); total body clearance (Cl)¼dose/AUC; volume of distribution
(Vd)¼Cl/b; elimination half-life (t1/2b)¼0.693/b; bioavailability
(%F)¼(AUCoral/AUCi.v.) 100. Pharmacokinetic data were ana-
lysed for differences in plasma 667 COUMATE concentrations
after p.o. or i.v. dosing using ANOVA.
Ex vivo investigations into the uptake and stabilisation of
667 COUMATE by RBCs
Whole blood was removed from female Wistar rats, pooled,
centrifuged (2800g,4 1C, 15min) and separated into RBCs and
plasma. 667 COUMATE (10mgml
 1), 667 COUMARIN
(10mgml
 1) or vehicle only (THF) were added to plasma and
mixed with an equivalent volume of RBCs. 667 COUMATE was
also incubated with plasma only. Duplicate samples were
maintained at 371C for 0.5, 1, 3 and 24h on rollers. Whole blood
was acidified by addition of 1 M (pH 3) citrate buffer (9:1, vv
 1).
In order to determine the extent of 667 COUMATE sequestration
by RBCs, plasma and RBCs were separated by centrifugation
(2800g,4 1C, 15min) and reconstituted to whole blood by addition
of an equivalent volume of blank RBCs or plasma, respectively. 667
COUMATE and 667 COUMARIN were extracted from ‘whole
blood’ as described previously. The effect of the carbonic
anhydrase inhibitor acetazolamide (100mM) on the uptake of 667
COUMATE and 667 COUMARIN into RBCs was also investigated
by preincubation with whole blood for 30min, prior to addition of
667 COUMATE or 667 COUMARIN. For the uptake of [
3H]667
COUMATE (19pmol, 1.26 10
6dpm), the agent was incubated
with whole blood (1ml) for 30min. Plasma was separated from
other blood constituents by centrifugation (2800g,4 1C, 15min)
and the radioactivity was counted.
High-performance liquid chromatography analysis
667 COUMATE was separated from its putative metabolite 667
COUMARIN using a reversed-phase HPLC method described
previously (Ireson et al, 2003). Briefly, an Agilent 1100 (Cheshire,
UK) autosampler, photodiode array detector, solvent delivery
system and C3-phenyl column (250 5mm, 5mM) purchased from
Phenomenex (Cheshire, UK) were used to determine the levels of
667 COUMATE in plasma and whole blood. Plasma calibration
curves were found to be linear from 0.1 to 40mgml
 1. The limit of
detection of 667 COUMATE in plasma was 0.1ngml
 1. The
coefficients of variation (interday and intraday) were o10%.
Software
Chromatograms were generated using Agilent Chemstation Soft-
ware. The figures were prepared using Prism version 3 obtained
from Graphpad Software, San Diego.
RESULTS
Stability of 667 COUMATE in vehicle
To ascertain that 667 COUMATE is stable in the vehicle used, the
agent was incubated on ice for up to 6h. High-performance liquid
chromatography analysis of the drug in this vehicle at various time
points revealed that 667 COUMATE is stable when maintained
under these conditions. 667 COUMARIN, the major degradation
product of 667 COUMATE, was below the limit of detection.
Pharmacokinetics of 667 COUMATE
In order to determine the pharmacokinetic parameters of 667
COUMATE, plasma concentrations were measured following
administration of a single p.o. or i.v. dose to female rats (Figure
2A–D). 667 COUMARIN, which is generated by degradation of 667
COUMATE in plasma ex vivo (Ireson et al, 2003), was only a minor
metabolic product of 667 COUMATE in vivo (Figure 2B and C). A
log concentration vs time plot showed linear kinetics following
both dosing routes. The linear kinetics was indicative of zero order
pharmacokinetics, and therefore a noncompartmental model was
used for analysis of the data (Table 1). 667 COUMATE could be
detected for up to 8h after i.v. and p.o. administration, after which
the levels were below the limit of detection (Figure 3). The
maximum level of 667 COUMATE in plasma was attained 30min
after oral dosing. The half-life of 667 COUMATE in plasma was 1.2
and 2h after i.v. and p.o. dosing, respectively. The bioavailability
of 667 COUMATE was approximately 95%. Plasma concentrations
of 667 COUMATE were significantly higher 5 and 15min after i.v.
dosing than after p.o. administration (Po0.001). At all other time
points examined, no significant differences in plasma concentra-
tions resulting from i.v. or p.o. dosing were detected.
Figure 2 High-performance liquid chromatograms of diethyl ether
extracts of rat plasma (A–C) or RBCs (D) 30min after administration of
(A) vehicle only, (B) 667 COUMATE i.v., (C) 667 COUMATE p.o. and
(D) 667 COUMATE p.o. 7-Hydroxycoumarin, added as the internal
standard, 667 COUMARIN and 667 COUMATE are denoted by 1, 2 and
3, respectively. For details of extraction and HPLC method, see Materials
and Methods.
Table 1 Summary of 667 COUMATE pharmacokinetic data after
10mgkg
 1 bolus i.v. or p.o. administration
PK parameters i.v. p.o.
Cmax (mgml
 1) 22.870.6 11.970.4
Elimination rate constant (b)( h
 1) 0.670.02 0.370.1
t1/2b (h) 1.270.1 1.9770.3
AUC (hmgml
 1) 35.871.3 34.471.1
Vd (mlkg
 1) 93.972.9 153.2718.7
Cl (mlh
 1) 53.572.6 54.272.4
%F (bioavailability) — 95.976.1
Values shown are mean7s.e.m. (n¼3).
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We investigated the uptake of 667 COUMATE by RBCs both ex
vivo and in vivo. Following incubation of 667 COUMATE with
whole rat blood for 30min, more than 80% of the agent was found
to be associated with the RBC fraction (Figure 4). This was
confirmed by showing that the uptake of radiolabelled 667
COUMATE was also greater than 70%. At 24h following addition
of the drug to whole rat blood, only 48% of the agent was retained
by the RBCs. We also established that 667 COUMATE is taken up
by RBCs in vivo in the rat. The concentrations of 667 COUMATE
in RBCs 30min following administration of the agent p.o. and i.v.
were 12 and 19mgml
 1, respectively.
In order to provide evidence that the interaction between CAII
and 667 COUMATE is important in the sequestration of the agent
by RBCs, whole rat blood was preincubated with the CAII inhibitor
acetazolamide. Following incubation with the inhibitor, the uptake
of 667 COUMATE into RBCs was reduced to 50%. The uptake of
667 COUMARIN, the degradation product of 667 COUMATE, was
50% and preincubation of blood with acetazolamide did not affect
this uptake.
Stabilisation of 667 COUMATE by RBCs
The stability of 667 COUMATE in plasma and whole blood was
compared by calculating the ratio of 667 COUMATE/667
COUMARIN at various time points after addition of the agent to
these biological fluids. At 30min after the addition of 667
COUMATE to whole blood and plasma, the ratios of 667
COUMATE:667 COUMARIN were 5.1 and 1.5, respectively
(Figure 5). When the agent had been incubated with whole blood
for 3h, the ratio was 3.9. In contrast, parent compound 667
COUMATE was below the limit of detection in plasma following a
3h incubation.
DISCUSSION
667 COUMATE inhibits rat liver STS by 93% at 10mgkg
 1 and
causes a reduction in the growth of E1S-stimulated tumours in the
nitrosomethylurea-induced rat mammary model (Purohit et al,
2000, 2001). The pharmacokinetics of this agent have not
previously been investigated. In this study, we elucidated the
pharmacokinetic parameters of 667 COUMATE following a single
i.v. and p.o. dose of the agent. The clearance rates for 667
COUMATE were 53 and 54mlh
 1 following i.v. or p.o. dosing,
respectively, suggesting fast removal of 667 COUMATE from the
plasma. Such rapid clearance rates would normally indicate that
the plasma levels should also fall quickly but this was found not to
be the case as significant concentrations of 667 COUMATE were
still detectable for up to 8h. In this study, however, we found that
the bioavailability of 667 COUMATE is 95% and that the plasma
concentrations of this agent are greater than 0.1mgml
 1 even 8h
after administration of a single p.o. or i.v. dose. 667 COUMATE
exhibited a zero order pharmacokinetic profile (Figure 3) when
administered via an intravenous route, indicating that it only
distributes into one compartment, the blood. However, 667
COUMATE demonstrated a high volume of distribution after oral
dosing (153.2mlkg
 1) compared to that after dosing i.v.
Figure 3 Plasma concentrations of 667 COUMATE after administration of a single p.o. or i.v. dose of 667 COUMATE to female Wistar rats. The values
shown in the figure are the means of three animals7s.e.m.
Figure 4 Percentage uptake of 667 COUMATE by rat RBCs following
incubation of the agent with whole rat blood maintained at 371C on rollers.
The coefficients of variation between samples were calculated to be less
than 10%. For details of extraction of 667 COUMATE from whole blood,
see Materials and Methods (means, n¼6).
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 1). This may be due to the difference in the elimination
rate constant after oral dosing. The difference in the elimination
rate constants may be a consequence of the steady uptake of 667
COUMATE by RBCs following oral absorption, as opposed to the
putative rapid saturation of RBC uptake following a bolus i.v. dose,
although this remains to be experimentally confirmed. The finding
that p.o. administration of 667 COUMATE resulted in similar
plasma concentrations to those achieved after i.v. dosing indicates
that it will be feasible to give the drug orally when used clinically. It
is apparent from this study that 667 COUMATE is relatively
resistant to metabolism as no evidence of any conversion to 667
COUMARIN, or other metabolites, was detected. Although tissue
concentrations of 667 COUMATE were not measured in the
present study, it has been shown to almost completely inhibit STS
activity in nitrosomethylurea–induced mammary tumours in rats,
indicating that the drug is effectively delivered to target tissues
(Purohit et al, 2000).
Several studies have demonstrated that RBCs may have a role in
the transport of chemotherapeutic agents prominent among which
are methotrexate (Lena et al, 1987) and 5-fluorouracil (Baerlocher
et al, 1997). In this study, we set out to determine whether 667
COUMATE is sequestered into RBCs, as this may explain the high
bioavailability of this agent despite its relatively high clearance
rate. Using two independent analytical methods, we found that
when 667 COUMATE is added to rat whole blood ex vivo, more
than 70% of the agent is taken up by RBCs. We also found that 667
COUMATE is sequestered into RBCs in vivo. These findings have
stimulated research to identify the site to which 667 COUMATE
binds in these cells. It is well known that sulphonamide drugs, such
as acetazolamide, which are structurally related to sulphamates
through the sulphamido group, can bind to CAII and inhibit its
activity (Casini et al, 2003). The ability of 667 COUMATE to dock
into the CAII active site and inhibit its activity by sulphamate
coordination to the enzyme zinc atom was therefore examined (Ho
et al, 2003; Vicker et al, 2003). In addition to being active as an STS
inhibitor, 667 COUMATE proved to be also a potent inhibitor of
CAII activity in an enzyme preparation derived from RBCs.
Evidence from docking studies and CAII inhibition studies
suggests that once taken up by RBCs, 667 COUMATE interacts
with CAII (Vicker et al, 2003). The related steroid sulphamate,
EMATE, has been cocrystallised with CAII and the sulphamate–
zinc interaction confirmed (Abbate et al, 2004). When whole blood
was preincubated with the CAII inhibitor acetazolamide, the
uptake of 667 COUMATE was reduced to 50%. Consequently, it
appears that the interaction of 667 COUMATE with CAII is
essential if the agent is to be retained by the RBCs. Studies with
other sulphamoylated agents have shown that this interaction is
reversible (Ho et al, 2003). In this study, we show that 667
COUMATE is above the limit of detection in plasma 8h after
administration of a single i.v. or p.o. bolus of the agent.
Furthermore, when the STS inhibitor was incubated with whole
blood ex vivo, only 48% of the agent was associated with the RBC
fraction after 24h. These data suggest that the interaction of 667
COUMATE with CAII is reversible, although this remains to be
experimentally confirmed.
The novel anticancer sulphonamide drug E7070, which is
currently undergoing clinical trials, is also taken up by RBCs
and this may account for its nonlinear pharmacokinetic profile in
humans (Yoshino et al, 1999; Terret et al, 2003; Van den Bongard
et al, 2003). Like 667 COUMATE, E7070 is also a potent carbonic
anhydrase inhibitor (Supuran, 2003). Expression of carbonic
anhydrases is increased in some tumours where their action to
acidify the extracellular environment may give tumours a growth
advantage over normal tissues (McKierman et al, 1997; Tureci et al,
1998). Thus, its ability to inhibit carbonic anhydrase activity may
contribute to the anticancer efficacy of 667 COUMATE, in addition
to its potent STS inhibitory properties.
In our next series of experiments, we investigated the hypothesis
that the RBCs provide a sanctuary for 667 COUMATE and protect
it from hydrolytic degradation in the plasma. When 667
COUMATE was incubated with plasma, the agent was below the
limit of detection after 3h. In marked contrast, when 667
COUMATE was incubated with whole blood, the agent could still
be detected after 48h. The stabilisation of 667 COUMATE by RBCs
may explain why 667 COUMATE, despite its modest stability in
plasma, can be detected in plasma for up to 8h following a single
dose and can inhibit hepatic STS in vivo in the rat for up to 24h
(Purohit et al, 2001). Aryl sulphamates inhibit CAII by binding of
the sulphamate moiety to the central zinc ion. Away from this site,
the binding site is predominantly hydrophobic and a rigid
hydrophobic steroid structure is well accommodated in this site
(Abbate et al, 2004). 667 COUMATE binds to CAII with an IC50
value of 17nM. As it is a good inhibitor, the more polar coumarin
motif must be well accommodated in the hydrophobic site. Since
degradation of 667 COUMATE is most likely to be via a b-
elimination mechanism involving development of charge on the
coumarin moiety in the transition state, it seems logical that in a
hydrophobic environment, this elimination mechanism is sup-
pressed by this enzyme. This mechanism should be even more
favoured here, since sulphamates bind to the CAII zinc as the
mono-anion and formation of this mono-anion should stimulate
the b-elimination process. Crystallisation of 667 COUMATE with
CAII is underway and should provide further insight into these
proposed mechanisms.
In conclusion, we show that 667 COUMATE is orally bioavail-
able, despite undergoing rapid degradation in rat plasma. We
found that 667 COUMATE is both sequestered and stabilised by
RBCs. Therefore, RBCs may protect 667 COUMATE from
degradation/metabolic clearance and transport the agent to tissues.
These processes may impinge on the pharmacological efficacy of
the agent in vivo and they support further clinical evaluation of 667
COUMATE as a novel chemotherapeutic agent.
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